PR: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
- PDF File: images/files//2022/20170125_pm_lizenz-max-delbruck-zentrum_eng_final.pdf
- Datum: Wednesday, 25 January 2017 11:29
- Created on .
- Last updated on .
- Hits: 1799